<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04963023</url>
  </required_header>
  <id_info>
    <org_study_id>PI2021_843_0051</org_study_id>
    <nct_id>NCT04963023</nct_id>
  </id_info>
  <brief_title>Biomarkers of Chronic Obstructive Pulmonary Disease</brief_title>
  <acronym>BIOBPCO</acronym>
  <official_title>Specific Biomarker Identification of Different Subgroups of Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are few studies about immunological explorations in COPD. Because of the complications&#xD;
      of lung biopsies, analyses are generally made on blood samples instead of lung tissue. No&#xD;
      study tried to classify COPD vs Asthma vs ACOS. The investigators wondered if there were&#xD;
      differences in biomarkers between these groups. The investigators decided to open a&#xD;
      pilot-study among COPD patients followed in Amiens-University Hospital. Each patient will be&#xD;
      examined and a blood-test will be performed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>identification specific blood immunologic marker for COPD</measure>
    <time_frame>one hour</time_frame>
    <description>COPD biomarkers are blood immunologic markers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete blood count (CBC) Variation between COPD and asthmatic patients</measure>
    <time_frame>one hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>c-reactive protein concentration variation between COPD and asthmatic patients</measure>
    <time_frame>one hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma protein electrophoresis profile Variation between COPD and asthmatic patients</measure>
    <time_frame>one hour</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>COPD</condition>
  <condition>Asthma-COPD Overlap Syndrome</condition>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>frequent exacerbation patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>non frequent exacerbation patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Asthma-and-COPD overlap syndrome</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Asthmatic patients (without COPD)</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Physical examinations</intervention_name>
    <description>BPCO physical examinations</description>
    <arm_group_label>Asthma-and-COPD overlap syndrome</arm_group_label>
    <arm_group_label>Asthmatic patients (without COPD)</arm_group_label>
    <arm_group_label>frequent exacerbation patients</arm_group_label>
    <arm_group_label>non frequent exacerbation patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>blood test</intervention_name>
    <description>blood test in order to study immunologic markers</description>
    <arm_group_label>Asthma-and-COPD overlap syndrome</arm_group_label>
    <arm_group_label>Asthmatic patients (without COPD)</arm_group_label>
    <arm_group_label>frequent exacerbation patients</arm_group_label>
    <arm_group_label>non frequent exacerbation patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        chronic obstructive pulmonary disease (COPD) patients, followed in Amiens-University&#xD;
        Hospital&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BPCO patients&#xD;
&#xD;
          -  ACOS patients&#xD;
&#xD;
          -  asthmatic patient without BPCO&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  infection&#xD;
&#xD;
          -  exacerbation&#xD;
&#xD;
          -  immunosuppressive treatment&#xD;
&#xD;
          -  immunosuppressive disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>MÃ©lanie DRUCBERT, MD</last_name>
    <phone>03 22 04 59 10</phone>
    <email>drucbert.melanie@chu-amiens.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Claire ANDREJAK, Pr</last_name>
    <email>andrejak.claire@chu-amiens.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80480</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire ANDREJAK, Pr</last_name>
      <phone>(33)3.22.08.79.98</phone>
      <email>andrejak.claire@chu-amiens.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 17, 2021</study_first_submitted>
  <study_first_submitted_qc>July 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2021</study_first_posted>
  <last_update_submitted>July 5, 2021</last_update_submitted>
  <last_update_submitted_qc>July 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Asthma-COPD Overlap Syndrome</keyword>
  <keyword>Asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

